Contact

Maladie d’Alzheimer : un rôle protecteur des dégénérescences neurofibrillaires ?

​Les larges agrégats de protéines Tau observés dans les neurones des personnes atteintes de la maladie d’Alzheimer sont considérés comme étant au moins partiellement à l’origine de la maladie. Une étude conduite par des chercheurs de MIRCen (Institut de biologie François Jacob/CEA, NeurATRIS) suggère au contraire que ces dégénérescences neurofibrillaires (DNF) joueraient un rôle protecteur. 

Read more...

Plasma Amyloid is modulated by age and seasonal rhythms in mouse lemur primates

Accumulation of amyloid-β (Aβ) peptides in the brain is a critical early event in the pathogenesis of Alzheimer's disease (AD), the most common age-related neurodegenerative disorder. There is increasing interest in measuring levels of plasma Aβ since this could help in diagnosis of brain pathology. However, the value of plasma Aβ in such a diagnosis is still controversial and factors modulating its levels are still poorly understood.

Read more...

NeurATRIS @ BioEurope Spring 2018

The 12th annual international partnering conference BioEurope Spring will take place March 12-14, 2018, in Amsterdam.

With a focus on European innovation and global collaboration, BIO-Europe Spring is the premier springtime partnering conference bringing together a “whoʼs who” from biotech, pharma and finance in the most innovative biopharma clusters in Europe.

Ali Aït-Ikhlef, NeurATRIS business development manager, will be there: This email address is being protected from spambots. You need JavaScript enabled to view it.and meet him there !

Call for collaborative projects

NeurATRIS launches a call aimed at fostering collaborative projects between NeurATRIS members and scientific community (academic and clinical laboratories and biotech companies) involved in neurodegenerative disease projects with a grant up to 50 000 € for the successful applicants.

Academic research laboratories and biotechs are welcome to apply. Applicant consortia may include a private partner, but only academics and biotechs will be eligible for funding.

Read more...